Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications

International Journal of Pharmaceutics

Volumn 370, Issue 1-2, 2009, Pages 41-46

  Kayitare, E ^a   Vervaet, C ^b   Ntawukulilyayo, J D ^a   Seminega, B ^a   Bortel, Van ^c   Remon, J P ^b  

^a UNIVERSITY OF RWANDA   (Rwanda)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Antiretroviral fixed dose combination; Paediatric drug formulations

Indexed keywords

AEROSIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; STARCH GLYCOLATE SODIUM; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDICATION; DRUG MIXTURE; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; FIXED DOSE COMBINATION TABLET; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MOLECULAR WEIGHT; NORMAL HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; TABLET; TABLET DISINTEGRATION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG COMPOUNDING; FEMALE; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PEDIATRICS; REVERSE TRANSCRIPTASE INHIBITORS; SOLUBILITY; TABLETS; ZIDOVUDINE;

EID: 61349097220     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.11.005     Document Type: Article

References (37)

1. American Academy of Pediatrics, 2007. Increasing Antiretroviral Drug Access for Children With HIV infection, Committee on Pediatric AIDS, Section on International Child Health. Pediatrics 119, 838-845.
2. European Pharmacopoeia. Uniformity of mass of single-dose preparations. 3rd edition (1997) pp. 133-134
3. Food and Drug Administration, 2003. Guidance for Industry: Bioavailability and Bioequivalence Studies for orally administered Drug Products-General considerations, 1-26 Available at www.fda.gov/cder/guidance/5356fnl.pdf. (Accessed 5.3.07).
4. Gonnissen Y., Verhoeven E., Peeters E., Remon J.P., and Vervaet C. Coprocessing via spray drying as a formulation platform to improve the compactibility of various drugs. Int. J. Pharm. Biopharm. 69 (2008) 320-334
5. Gupta P., and Gupta K. Broken tablets: does the sum of parts equal the whole?. Am. J. Hosp. Pharm. 45 (1988) 1498
6. Kano E.K., dos Reis Serra C.H., Koono E.E.M., Andrade S.S., and Porta V. Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies. Int. J. Pharm. 297 (2005) 73-79
7. Kayumba P.C., Huyghebaert N., et al. Quinine sulfate pellets for flexible pediatric drug dosing: Formulation development and evaluation of taste-masking efficient using the electronic tongue. Eur. J. Pharm. Biopharm. 66 (2007) 460-465
8. Kayumba P.C., Twagirumukiza M., Huyghebaert N., et al. Taste-masking quinine sulphate pellets: bio-availability in adults and stead-state plasma concentrations in children with uncomplicated Plasmodium falciparum malaria. Ann. Trop. Paedrics 28 (2007) 103-109
9. Kristensen H.G., Jorgensen G.H., and Sonnergaard J.M. Mass uniformity of tablets broken by hand. Pharmeuropa 7 2 (1995) 298-302
10. Legorreta A., Yu A., Chernicoff H., Gilmore A., Jordan J., and Rosenzweig J.C. Adherence to combined lamivudine plus zidovudine versus individual components: a community-based retrospective Medicaid claims analysis. AIDS Care 17 (2005) 938-948
11. MacDevitt J.T., Gurst A.H., and Chen Y. Accuracy of tablet splitting. Pharmacotherapy 18 1 (1998) 193-197
12. Makino T., Imoto S., Mizukami Y., Marunaka S., and Kitamori N. Design and evaluation of scored tablets. Jpn. J. Hosp. Pharm. 19 (1993) 280-286
13. Marriot J.L., and Nation L. Splitting tablets. Aust. Prescriber 25 (2002) 133-135
14. Menson E.N., Walker A.S., Sharland M., Wells C., et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines in children 1997-2005: cohort study. Brit. Med. J. 332 (2006) 1183-1187
15. Mizumoto T., Masuda Y., Yamamoto T., Yonemochi E., and Terada K. Formulation design of a novel fast-disintegrating tablet. Int. J. Pharm. 306 (2005) 83-90
16. Narang V.S., Lulla A., Malhotra G., and Purandare S. Pharmacokinetic profiling and bioequivalence evaluation of two lamivudine tablets formulations After Single Oral Administration in Healthy Human Indian Volunteers. J. Acquir. Immun. Defic. Syndr. 5 38 (2005) 566-569
17. National Prescribing Centre, 2000. Prescribing for children, MeRec Bull. 11, 1-4. Available at www.npc.co.uk/MeReC_Bulletins/2000Volumes/pdfs/vol11n02.pdf.
18. Newell M.L., Coovadia H., Cortina Borja M., et al. Mortality of Infected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364 (2004) 1236-1243
19. Nunn T., and Williams J. Formulation of medicines for children. Brit. J. Clin. Pharmacol. 59 (2005) 674-676
20. Pai N., and Desai A.D. Simultaneous reverse phase HPLC estimation of some antiretroviral drugs from tablets. Ind. J. Pharm. Sci. 69 (2007) 118-120
21. Pharmaeuropa, 2004. Breaking of scored tablets 16, 250-251.
22. Polli J.E., Sharon J., and Martin B.R. Weight uniformity of split tablets required by a veteran affairs policy. J. Manage. Care Pharm. 9 (2003) 401-407
23. Rodenhuis N., De Smet P., and Barends D.M. The rationale of score tablets as dosage form. Eur. J. Pharm. Sci. 21 (2004) 305-308
24. Rogers M.F., Thomas P.A., Starcher E.T., Noa M.C., Bush T.J., and Jaffe H.W. Acquired immunodeficiency syndrome in children. Paediatrics 79 (1987) 1008-1014
25. Rouzioux C., Costagliola D., and Burgard M. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am. J. Epidemiol. 142 (1995) 1330-1337
26. Standing J.F., and Tuleu C. Paediatric formulations-getting to the heart of the problem. Int. J. Pharm. 300 (2005) 56-66
27. The United State Pharmacopoeia USP 27, 2004, 2302-2304.
28. Therapeutic systems research laboratories. Available at www.tsrlinc.com/service/bcs.
29. Thonissen T., Joyce P., Van Durme J., and Slegers G. Statistical analysis of tablet breakability methods. J. Pharm. Sci. 5 (2002) 190-198
30. ICH Topic E11, 2003. Guidance for Industry: Clinical Investigation of Medical Products in the Pediatric Population, Health Canada, pp. 1-15.
31. United Nations Children's Fund/World Health Organization, 2004. UNICEF/WHO technical consultation: improving access to appropriate ARV formulations-November 3-4, 2004. Available at: www.who.int/3by5/en/finalreport.pdf. (Accessed 18.01.08).
32. Van Santen E., Barendsm D.M., and Frijlink H.W. Breaking of scored tablets: a review. Eur. J. Pharm. Biopharm. 53 (2002) 139-145
33. Vezina H.E., Henry K., Ravindran G.D., Kurppad A.V., et al. A randomized crossover study to determine bioequivalence of generic and brand name Nevirapine, Zidovudine and Lamivudine in HIV-Negative Women in India. J. Acquir. Immun. Defic. Syndr. 41 (2006) 131-136
34. Wilson M.M., Kaiser F.E., and Morley J.E. Tablet breaking ability of older diabetic persons. J. Am. Geriat. Soc. 44 (1996) 106
35. World Health Organisation, 2006. Paediatric guideline on Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. 25-36 Available at: www.who.int/hiv/pub/guidelines/WHOpaediatric.pdf.
36. World Health Organization, 2006. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. Available at: www.who.int/hiv/fullreport_en_highres.pdf. (Accessed 20.04.08).
37. Yeung V.W., and Wong I.C.K. When do children convert from liquid antiretroviral to solid formulations. Pharm. World Sci. 27 (2005) 399-402